Sec­ondary patents prove to be key in biosim­i­lar block­ing strate­gies, re­searchers find

While the US biosim­i­lars in­dus­try has gen­er­al­ly been a dis­ap­point­ment since its in­cep­tion, with FDA ap­prov­ing 33 biosim­i­lars since 2015, just a frac­tion of those …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER